AlloNK (AB-101) — Topline data
H2 2028
We are initiating the registrational trial in the second half of 2026 and expect to report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029.Source filing
ARTV biotech catalysts & pipeline
ARTIVA BIOTHERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
AlloNK (AB-101) — NDA/BLA submission
2029
We are initiating the registrational trial in the second half of 2026 and expect to report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029.Source filing